Navigation Links
New compound holds promise for treating Duchenne MD, other inherited diseases
Date:6/27/2012

Scientists at UCLA have identified a new compound that could treat certain types of genetic disorders in muscles. It is a big first step in what they hope will lead to human clinical trials for Duchenne muscular dystrophy.

Duchenne muscular dystrophy, or DMD, is a degenerative muscle disease that affects boys almost exclusively. It involves the progressive degeneration of voluntary and cardiac muscles, severely limiting the life span of sufferers.

In a new study, senior author Carmen Bertoni, an assistant professor in the UCLA Department of Neurology, first author Refik Kayali, a postgraduate fellow in Bertoni's lab, and their colleagues demonstrate the efficacy of a new compound known as RTC13, which suppresses so-called "nonsense" mutations in a mouse model of DMD.

The findings appear in the current online edition of the journal Human Molecular Genetics.

"We are excited about these new findings because they represent a major step toward the development of a drug that could potentially treat this devastating disease in humans," Bertoni said. "We knew that the compounds were effective in cells isolated from the mouse model for DMD, but we did not know how they would behave when administered in a living organism."

Nonsense mutations are generally caused by a single change in DNA that disrupts the normal cascade of events that changes a gene into messenger RNA, then into a protein. The result is a non-functioning protein. Approximately 13 percent of genetic defects known to cause diseases are due to such mutations. In the case of DMD, the "missing" protein is called dystrophin.

For the study, Bertoni and Kayali collaborated with the laboratory of Dr. Richard Gatti, a professor of pathology and laboratory medicine and of human genetics at UCLA. Working with the UCLA Molecular Shared Screening Resource facility at the campus's California NanoSystems Institute, the Gatti lab screened some 35,000
'/>"/>

Contact: Mark Wheeler
mwheeler@mednet.ucla.edu
310-794-2265
University of California - Los Angeles
Source:Eurekalert

Page: 1 2

Related biology news :

1. Nonstoichiometric Compounds V - An ECI Conference Series
2. New drug-screening method yields long-sought anti-HIV compounds
3. Dont feel like exercise? Scientists find compound that may help you work out harder
4. Nuisance seaweed found to produce compounds with biomedical potential
5. Like curry? New biological role identified for compound used in ancient medicine
6. Heparin-like compounds inhibit breast cancer metastasis to bone
7. Sulphur and iron compounds common in old shipwrecks
8. New screening technique yields elusive compounds to block immune-regulating enzyme
9. Biosensor illuminates compounds to aid fight against TB
10. Canadian girl, 16, invents disease-fighting, anti-aging compound using tree particles
11. Remote Siberian lake holds clues to Arctic -- and Antarctic -- climate change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... researchers have developed a unique method to use microbes ... rural areas. , The first microbe-powered, self-sustaining wastewater ... way to clean up waste from large farming operations ... , Professor Haluk Beyenal and graduate student Timothy Ewing ... the system in the online edition of Journal ...
(Date:9/18/2014)... into the Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne ... similar to that caused by Ebolavirus, has identified new ... the potential to lead to novel targets for therapeutic ... reported in a paper published today in the journal ... the Texas Biomedical Research Institute and their colleagues, represents ...
(Date:9/18/2014)... times it,s demonstrated, it,s still hard to envision ... by using a signaling system called "quorum sensing," ... suit their population. In short, some bacteria "know" ... accordingly. , Once the population of quorum-sensing bacteria ... to pathogenic, or from unhelpful to helpful. The ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Research milestone in CCHF virus could help identify new treatments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... a paper published in the October 2011 issue of ... researchers at Columbia University Medical Center led by Stephen ... photoreceptors in a mouse model for retinitis pigmentosa (RP) ... a heterogeneous disorder characterized by progressive degeneration of rod ...
... Calif., Sept. 30, 2011 A glucosamine-like dietary supplement ... according to a UC Irvine study. UCI,s Dr. ... N-acetylglucosamine (GlcNAc), which is similar to but more effective ... function of abnormal T-cells that in MS incorrectly direct ...
... Perez Olsen, Ph.D., a Weintraub Scholar in the Basic ... the recipient of the National Institutes of Health Director,s ... first group of 10 junior U.S. investigators to receive ... million to support their research over a five-year period; ...
Cached Biology News:Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 2Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 3Glucosamine-like supplement suppresses multiple sclerosis attacks 2Hutchinson Center scientist wins first NIH Director's Early Indpendence Award 2
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics (NASDAQ: ... preclinical studies characterizing the analgesic profiles of a ... opioid receptor agonist molecules. The preclinical research candidates ... chemistry platform. The analgesic properties of ... medical literature. 1,2 Kappa opioid receptors are ...
(Date:9/19/2014)... Dublin ... announced the addition of the  "Micro Market Monitor ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... fastest-growing segments in the chromatography market. The market ... expected to reach $2.0 billion by 2019, at ...
(Date:9/18/2014)... 18, 2014 About POCT ... outside a clinical laboratory. It helps in making ... treatments and medication. POCT is gaining popularity due ... diseases such as diabetes, heart disease, and obesity. ... are standardized to minimize errors during the diagnosis ...
(Date:9/18/2014)... Texas Governor Rick Perry, Texas ... Health Science Center CEO Brett Giroir, M.D., and ... Human Services (HHS), State of Texas and biopharmaceutical ... vaccine manufacturing facility in Bryan, Texas, which when ... Texas A&M Biocorridor – a rapidly evolving hub ...
Breaking Biology Technology:Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4
... S.C., Dec. 1 Collexis Holdings, Inc.,(OTC ... semantic search and,knowledge discovery software, announced today ... association, to promote BiomedExperts.com,to the association,s 200+ ... as the primary professional network for,BioFlorida, helping ...
... company aided in the research of vein treatment methods led by Dr. ... develop a new medical device, which he will present this summer to ... ... 1, 2008-- A gift from a California company aided in the research ...
... Encorium Group, Inc.,(Nasdaq: ENCO ), a ... over 30 countries for many of the world,s leading,pharmaceutical ... it received a letter from Nasdaq stating that since ... period ended September 30, 2008 as of the,date of ...
Cached Biology Technology:BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 2BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 3BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 4Gift Aids Professor's Research into Vein Treatment 2Gift Aids Professor's Research into Vein Treatment 3Gift Aids Professor's Research into Vein Treatment 4Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing 2Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing 3
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... microRNA Microarray contains all known fish ...
... unique quantitative and qualitative capabilities of the ... LC/MS/MS Systems with the new Tempo nano ... a rapid solution for high sensitivity validation ... extensive sample preparation with high instrument selectivity ...
... of Agilent analytical solutions is the 6890N ... (LAN) allows you to share business and ... decision making. Just as its 6890 GC ... and performance needed for research and method ...
... The 6820 GC system combines world-class performance ... QA/QC software, Agilents world-renowned support and columns, ... and supplies--a combination that lets you reach ... based on dependable data. The Agilent 6820 ...
Biology Products: